Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.

Huang, Xuan-Zhang; Jia, Han; Xiao, Qiong; Li, Run-Zhou; Wang, Xing-Shuang; Yin, Hai-Yan; Zhou, Xin.

Afiliação

Huang XZ; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.
Jia H; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Xiao Q; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.
Li RZ; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Wang XS; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Yin HY; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Zhou X; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Front Oncol ; 10: 958, 2020.

Article em En | MEDLINE | ID: mdl-32612955